We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New SARS-CoV-2 Kit Simultaneously Detects Four COVID-19 Variants with Single RT PCR Test

By LabMedica International staff writers
Posted on 12 Oct 2021

A new real-time PCR test kit is capable of simultaneously detecting four variants of COVID-19. More...

Kaneka Corporation (Tokyo, Japan) has launched its new KANEKA RT-PCR Kit SARS-CoV-2 (L452R/E484Q/E484K/N501Y), a real-time PCR test kit that is capable of simultaneously detecting four variants of COVID-19. The test kit uses a reagent developed using Kaneka's molecular testing-related technologies. The reagent makes it possible to simultaneously detect four mutations of the spike protein (the N501Y, E484K, E484Q, and L452R mutations) with a single PCR test. Based on the mutation detection patterns, it can efficiently detect two variants (the Alpha, Delta, Kappa, and Beta or Gamma variants).

The PCR kit for detecting COVID-19 released by Kaneka last year received approval in June of this year as KANEKA Direct RT-PCR kit SARS-CoV-2 for use as an In-Vitro Diagnostic reagent. It is widely used in medical facilities and testing centers. By adding this new COVID-19 variant PCR test kit to its lineup, the company is aiding the rapid detection of variants and the prevention of the spread of COVID-19.

Related Links:
Kaneka Corporation 


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Immunoassay Analyzer
Procise DX
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.